:format(webp)/cdn.mskdoctors.com/storage/2026/8/Ewh8g5cu43sIQRMxdnzj8fpnnY4s4jTS.jpg)
Questions to ask before a ChondroFiller injectionChondroFiller is a Type I collagen hydrogel injected into the joint where it recruits the patient's own progenitor cells to repair cartilage over months rather than days. Specific suitability criteria apply; questions a patient asks beforehand substantially influence whether expectations align with realistic outcomes.ChondroFiller is a Type I collagen hydrogel injected into the joint where it recruits the patient's own progenitor cells to repair cartilage over months rather than days. Specific suitability criteria apply; questions a patient asks beforehand substantially influence whether expectations align with realistic outcomes.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/m5hussZZ9owL5cSOW8JGtSBbGitjmL5I.jpg)
ChondroFiller repeat injections and long-term repairChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.ChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/0TUtcyt4GXbxiF6gJem8IBQTJxdBjdy1.jpg)
When cartilage repair is the right choiceCartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/NVBxTwqrhFf5MtzHXwBTNTJi8qrvNNkp.jpg)
Physiotherapist or surgeon first for a meniscus tearFor most meniscus tears, physiotherapy is the evidence-supported first step; surgery is reserved for lockedknees, persistent instability, or severe acute injuries that fail to settle.For most meniscus tears, physiotherapy is the evidence-supported first step; surgery is reserved for locked knees, persistent instability, or severe acute injuries that fail to settle.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/YhbMqNe7YBZk33LsalLldwHMFTQmXyhT.jpg)
ChondroFiller Injection Evidence Patients Should WeighInjected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.Injected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/Xc2EYraU36Mqzzl7yRSHjrrwbnM4pNVP.jpg)
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/Glw9JbiPP4VAFQxjx5hgGynC18Pe38KX.jpg)
Who qualifies for ChondroFiller injectionChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.ChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/Sw4oQf2mna5fkZ0kFwobf42ajcOyNZiY.jpg)
Ten-Year Success Rates for OATS MosaicplastyTen-year success rates for OATS mosaicplasty span 72–89% in young, active patients; failure rates drop to 12.5–14% in optimal candidates (under 40, lesion under 3 cm²) but rise to 38–40% in older patients with larger defects.Ten-year success rates for OATS mosaicplasty span 72–89% in young, active patients; failure rates drop to 12.5–14% in optimal candidates (under 40, lesion under 3 cm²) but rise to 38–40% in older patients with larger defects.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/avuNKQfAKHfoMbyfAZJlsUvqvncXbBev.jpg)
Choosing between ACI and MACI for cartilage repairMACI cartilage grafts show 90% fill at two years but decline to 49% by ten years; 73% become fibrocartilage rather than the hyaline cartilage needed for durability.MACI cartilage grafts show 90% fill at two years but decline to 49% by ten years; 73% become fibrocartilage rather than the hyaline cartilage needed for durability.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/Tc7BZVSZxTAg9ngXUcrH97k20o8iK8T0.jpg)
ChondroFiller injection versus cartilage surgeryChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/fI1OLTY4rXZmoPULfTGjujCUV9qyYume.jpg)
What separates ChondroFiller from Liquid CartilageChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/wqoVv4H89VNnXL9mTf6h0UPjYFBzX1Bs.jpg)
MACI recovery and return to sportMACI recovery takes twelve to eighteen months before high-impact sport. Most patients return to some sport, but only one-third reach their pre-injury level — a gap significantly driven by kinesiophobia, which clinical teams can screen and address through sports psychology support.MACI recovery takes twelve to eighteen months before high-impact sport. Most patients return to some sport, but only one-third reach their pre-injury level — a gap significantly driven by kinesiophobia, which clinical teams can screen and address through sports psychology support.
